Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Return on Sales (2016 - 2025)

Coherus Oncology's Return on Sales history spans 13 years, with the latest figure at 0.68% for Q4 2025.

  • For Q4 2025, Return on Sales rose 128.0% year-over-year to 0.68%; the TTM value through Dec 2025 reached 8.33%, up 565.0%, while the annual FY2025 figure was 8.33%, 92.0% down from the prior year.
  • Return on Sales for Q4 2025 was 0.68% at Coherus Oncology, down from 0.78% in the prior quarter.
  • Across five years, Return on Sales topped out at 74.05% in Q1 2024 and bottomed at 2.33% in Q1 2023.
  • The 5-year median for Return on Sales is 0.61% (2021), against an average of 4.9%.
  • The largest annual shift saw Return on Sales soared 7639bps in 2024 before it tumbled -7526bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 0.62% in 2021, then tumbled by -108bps to 1.3% in 2022, then soared by 33bps to 0.87% in 2023, then skyrocketed by 32bps to 0.6% in 2024, then skyrocketed by 215bps to 0.68% in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Return on Sales are 0.68% (Q4 2025), 0.78% (Q3 2025), and 33.41% (Q2 2025).